These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 35328587)

  • 21. Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis.
    Wang P; Wang J; Li D; Ke W; Chen F; Hu X
    J Nutr Biochem; 2020 Jul; 81():108363. PubMed ID: 32388250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of daily consumption of probiotic yogurt on liver enzymes, steatosis and fibrosis in patients with nonalcoholic fatty liver disease (NAFLD): study protocol for a randomized clinical trial.
    Ebrahimi-Mousavi S; Alavian SM; Sohrabpour AA; Dashti F; Djafarian K; Esmaillzadeh A
    BMC Gastroenterol; 2022 Mar; 22(1):102. PubMed ID: 35255811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies.
    Ebrahimzadeh Leylabadlo H; Ghotaslou R; Samadi Kafil H; Feizabadi MM; Moaddab SY; Farajnia S; Sheykhsaran E; Sanaie S; Shanehbandi D; Bannazadeh Baghi H
    Eur J Clin Microbiol Infect Dis; 2020 Apr; 39(4):613-627. PubMed ID: 31828683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Probiotic mixture improves fatty liver disease by virtue of its action on lipid profiles, leptin, and inflammatory biomarkers.
    Al-Muzafar HM; Amin KA
    BMC Complement Altern Med; 2017 Jan; 17(1):43. PubMed ID: 28086768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gut Microbiota as an Emerging Therapeutic Avenue for the Treatment of Nonalcoholic Fatty Liver Disease.
    Ralli T; Neupane YR; Saifi Z; Kohli K
    Curr Pharm Des; 2021; 27(46):4677-4685. PubMed ID: 34176456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut-liver axis.
    Delzenne NM; Knudsen C; Beaumont M; Rodriguez J; Neyrinck AM; Bindels LB
    Proc Nutr Soc; 2019 Aug; 78(3):319-328. PubMed ID: 30628563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-Administration of Cholesterol-Lowering Probiotics and Anthraquinone from Cassia obtusifolia L. Ameliorate Non-Alcoholic Fatty Liver.
    Mei L; Tang Y; Li M; Yang P; Liu Z; Yuan J; Zheng P
    PLoS One; 2015; 10(9):e0138078. PubMed ID: 26375281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota.
    Doulberis M; Kotronis G; Gialamprinou D; Kountouras J; Katsinelos P
    Metabolism; 2017 Jun; 71():182-197. PubMed ID: 28521872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
    Cho MS; Kim SY; Suk KT; Kim BY
    J Microbiol; 2018 Dec; 56(12):855-867. PubMed ID: 30377993
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Banerjee G; Papri SR; Satapathy SK; Banerjee P
    Curr Pharm Biotechnol; 2024; 25(4):426-433. PubMed ID: 37724669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.
    Miura K; Ohnishi H
    World J Gastroenterol; 2014 Jun; 20(23):7381-91. PubMed ID: 24966608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies.
    Meroni M; Longo M; Dongiovanni P
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31689910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Age-Related NAFLD: The Use of Probiotics as a Supportive Therapeutic Intervention.
    Campagnoli LIM; Marchesi N; Vairetti M; Pascale A; Ferrigno A; Barbieri A
    Cells; 2022 Sep; 11(18):. PubMed ID: 36139402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pediatric NAFLD: the Future role of Patient-Tailored Probiotics Therapy.
    Putignani L; Alisi A; Nobili V
    J Pediatr Gastroenterol Nutr; 2016 Jul; 63 Suppl 1():S6-8. PubMed ID: 27380600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Probiotics and non-alcoholic fatty liver disease in children and adolescents: a systematic review.
    Avelar-Rodríguez D; Peña-Vélez R; Popov J; Hill L; Ryan PM
    Rev Esp Enferm Dig; 2023 Aug; 115(8):418-427. PubMed ID: 36412490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
    Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
    World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy.
    Ma J; Zhou Q; Li H
    Nutrients; 2017 Oct; 9(10):. PubMed ID: 29035308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined Amelioration of Ginsenoside (Rg1, Rb1, and Rg3)-enriched Korean Red Ginseng and Probiotic Lactobacillus on Non-alcoholic Fatty Liver Disease.
    Kim JC; Jeon JY; Yang WS; Kim CH; Eom DW
    Curr Pharm Biotechnol; 2019; 20(3):222-231. PubMed ID: 30854954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Probiotics in non-alcoholic fatty liver disease: which and when.
    Abenavoli L; Scarpellini E; Rouabhia S; Balsano C; Luzza F
    Ann Hepatol; 2013; 12(3):357-63. PubMed ID: 23619251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease.
    Filipovic B; Lukic S; Mijac D; Marjanovic-Haljilji M; Vojnovic M; Bogdanovic J; Glisic T; Filipovic N; Al Kiswani J; Djokovic A; Kapor S; Kapor S; Bukumiric Z; Starcevic A
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.